Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,896,164
  • Shares Outstanding, K 105,188
  • Annual Sales, $ 675,040 K
  • Annual Income, $ 141,210 K
  • EBIT $ 66 M
  • EBITDA $ 56 M
  • 60-Month Beta 0.23
  • Price/Sales 5.99
  • Price/Cash Flow 29.27
  • Price/Book 6.05

Options Overview Details

View History
  • Implied Volatility 63.53% (-2.41%)
  • Historical Volatility 209.15%
  • IV Percentile 43%
  • IV Rank 26.23%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 1) 1.11 (3.10%)
  • Put/Call Vol Ratio 1.67
  • Today's Volume 1,121
  • Volume Avg (30-Day) 5,915
  • Put/Call OI Ratio 1.40
  • Today's Open Interest 63,336
  • Open Int (30-Day) 54,826
  • Expected Range 34.59 to 36.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.27
  • Number of Estimates 4
  • High Estimate 0.30
  • Low Estimate 0.18
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.99 +7.99%
on 12/31/25
86.57 -58.85%
on 12/16/25
-51.68 (-59.19%)
since 12/15/25
3-Month
32.99 +7.99%
on 12/31/25
89.00 -59.97%
on 12/15/25
-41.18 (-53.62%)
since 10/15/25
52-Week
32.99 +7.99%
on 12/31/25
117.33 -69.64%
on 03/31/25
-18.15 (-33.76%)
since 01/15/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors...

CORT : 35.77 (-3.43%)
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

LOS ANGELES , Jan. 15, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept...

CORT : 35.77 (-3.43%)
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT ) for violations...

CORT : 35.77 (-3.43%)
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman

Partner Reed Kathrein Urges Investors to Contact Firm

CORT : 35.77 (-3.43%)
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Corcept Therapeutics Incorporated (CORT)

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated")...

CORT : 35.77 (-3.43%)
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated (“Corcept” or the “Company”)...

CORT : 35.77 (-3.43%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT).  Such investors...

CORT : 35.77 (-3.43%)
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the...

CORT : 35.77 (-3.43%)
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman

SAN FRANCISCO , Jan. 6, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced...

CORT : 35.77 (-3.43%)
1 Healthcare Stock to Target This Week and 2 We Turn Down

1 Healthcare Stock to Target This Week and 2 We Turn Down

CORT : 35.77 (-3.43%)
OSCR : 17.69 (+5.99%)
VTRS : 12.82 (-2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 39.55
2nd Resistance Point 38.51
1st Resistance Point 37.78
Last Price 35.77
1st Support Level 36.01
2nd Support Level 34.97
3rd Support Level 34.24

See More

52-Week High 117.33
Fibonacci 61.8% 85.11
Fibonacci 50% 75.16
Fibonacci 38.2% 65.21
Last Price 35.77
52-Week Low 32.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar